Demographic characteristics, treatment and clinical outcomes in the positive PCR cohort
| A | SARS-CoV-2 positive | SARS-CoV-2 negative |
| N (% of total) | 32 (59.3) | 22 (40.7) |
| DK | 30 (73.2) | 11 (26.8) |
| US | 2 (15.4) | 11 (84.6) |
| Female, n (%) | 25 (83.3) | 17 (70.8) |
| DK | 23 (82.1) | 8 (72.7) |
| US | 2 (100.0) | 9 (81.8) |
| Age, median (range) | 48 (25–64) | 47 (26–67) |
| DK | 48 (25–64) | 47 (28–67) |
| US | 46 (40-52) | 47 (26–54) |
| Duration of ocrelizumab treatment (years), median (range) | 2.2 (1.0–5.7) | 2.0 (1.6–7.0) |
| DK | 2.8 (1.0–5.7) | 2.5 (1.7–3.8) |
| US | 4.1 (3.6–4.5) | 4.4 (1.6–7.0) |
| Latest Expanded Disability Status Scale (EDSS), median (range) | 2.75 (0.0–6.0) | 2.0 (0.0–6.0) |
| DK | 2.25 (0.0–5.0) | 1.5 (1.5–6.0) |
| US | 5.75 (5.5–6.0) | 1.5 (0.0–3.5) |
| B | SARS-CoV-2 positive | DK cohort | US cohort |
| Remdesivir taken, n | 4 | 4 | 0 |
| Sotrovimab taken, n | 13 | 12 | 1 |
| Evusheld prophylaxis, n | 1 | 0 | 7 (6 uninfected) |
| WHO score, median (range) | 2 (1–4) | 2 (1–4) | 2 (2) |
| Days from last OCR treatment until COVID-19, median (range) | 79.0 (14.0–393.0) | 81.5 (15.0–393.0) | 39.5 (14.0–65.0) |
| Days from third vaccine to COVID-19, median (range) | 114.0 (47.0–188.0) | 114.0 (47.0–188.0) | 106.5 (85.0–128.0) |
DK, Danish cohort; OCR, ocrelizumab.